{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epileptic+Encephalopathy",
    "query": {
      "condition": "Epileptic Encephalopathy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 62,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epileptic+Encephalopathy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:07:02.640Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04537832",
      "title": "Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Encoded Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "60 Months",
        "sex": "ALL",
        "summary": "6 Months to 60 Months"
      },
      "enrollment_count": 58,
      "start_date": "2021-01-18",
      "completion_date": "2023-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04537832"
    },
    {
      "nct_id": "NCT05737784",
      "title": "A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SCN2A-DEE",
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "PRAX-222 - Initial Dose",
          "type": "DRUG"
        },
        {
          "name": "PRAX-222 - Initial Ascending Doses",
          "type": "DRUG"
        },
        {
          "name": "PRAX-222 - Optional Ascending Doses",
          "type": "DRUG"
        },
        {
          "name": "PRAX-222 - Fixed Doses",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Praxis Precision Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 60,
      "start_date": "2023-04-13",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-08-21",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05737784"
    },
    {
      "nct_id": "NCT03572933",
      "title": "Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "CDKL5 Deficiency Disorder"
      ],
      "interventions": [
        {
          "name": "ganaxolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marinus Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 101,
      "start_date": "2018-06-30",
      "completion_date": "2021-05-28",
      "has_results": true,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03572933"
    },
    {
      "nct_id": "NCT06872125",
      "title": "A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "zorevunersen",
          "type": "DRUG"
        },
        {
          "name": "Sham Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stoke Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 170,
      "start_date": "2025-06-04",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06872125"
    },
    {
      "nct_id": "NCT06092346",
      "title": "A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "AMPD3, OMIM*102772, AMP Deaminase Deficiency",
        "AK1, OMIM *103000, Adenylate Kinase Deficiency",
        "AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency",
        "TPMT, OMIM *187680, Thoipurines, Poor Metabolism of",
        "IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11",
        "APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency",
        "HPRT1, OMIM *308000 Lesch-Nyhan Disease",
        "XDH, OMIM *607633, Xanthinuria Type 1",
        "SLC2A9, OMIM *606142 Hypouricemia",
        "SLC22A12, OMIM *607096 Hypouricemia",
        "PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease",
        "PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity",
        "AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia",
        "ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35",
        "ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency",
        "PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency",
        "ADA2, OMIM *607575,Sneddon Syndrome; VAIHS",
        "CAD, *1140120, Developmental and Epileptic Encephalopathy",
        "UPB1, OMIM *606673, Beta-ureidopropionase Deficiency",
        "DPYS, OMIM *613326, Dihydropyrimidinase Deficiency",
        "DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency",
        "DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis)",
        "UMPS, OMIM *613891, Orotic Aciduria",
        "NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency",
        "UNG, OMIM *191525, Hyper-IgM Syndrome 5",
        "AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2",
        "Purine-Pyrimidine Metabolism",
        "Metabolic Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "1 Month to 100 Years"
      },
      "enrollment_count": 999,
      "start_date": "2023-12-19",
      "completion_date": "2099-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06092346"
    },
    {
      "nct_id": "NCT04337697",
      "title": "Neonatal Seizure Registry - Developmental Functional EValuation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neonatal Seizure",
        "Hypoxic-Ischemic Encephalopathy",
        "Stroke",
        "Intracranial Hemorrhages",
        "Epilepsy",
        "Cerebral Palsy",
        "Intellectual Disability"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "2 Years to 8 Years"
      },
      "enrollment_count": 188,
      "start_date": "2020-03-15",
      "completion_date": "2025-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04337697"
    },
    {
      "nct_id": "NCT03166215",
      "title": "Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Developmental and/or Epileptic Encephalopathies"
      ],
      "interventions": [
        {
          "name": "TAK-935",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2017-08-17",
      "completion_date": "2018-09-19",
      "has_results": true,
      "last_update_posted_date": "2021-01-07",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Port Charlotte, Florida • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03166215"
    },
    {
      "nct_id": "NCT05226780",
      "title": "Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SCN8A Developmental and Epileptic Encephalopathy Syndrome"
      ],
      "interventions": [
        {
          "name": "NBI-921352",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "2 Years to 22 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-07-12",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05226780"
    },
    {
      "nct_id": "NCT02023866",
      "title": "Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inherited Mitochondrial Disease, Including Leigh Syndrome"
      ],
      "interventions": [
        {
          "name": "Cysteamine Bitartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 36,
      "start_date": "2014-05",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Stanford, California • Akron, Ohio + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02023866"
    },
    {
      "nct_id": "NCT07102524",
      "title": "Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SLC13A5 Citrate Transporter Disorder"
      ],
      "interventions": [
        {
          "name": "TSHA-105",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TESS Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "2 Years to 20 Years"
      },
      "enrollment_count": 2,
      "start_date": "2025-12-01",
      "completion_date": "2031-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-05-22T03:07:02.640Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07102524"
    }
  ]
}